Literature DB >> 26690702

Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.

Jian Yu, Liguang Chen, Bing Cui, George F Widhopf, Zhouxin Shen, Rongrong Wu, Ling Zhang, Suping Zhang, Steven P Briggs, Thomas J Kipps.   

Abstract

Evolutionarily conserved receptor tyrosine kinase–like orphan receptor-1 and -2 (ROR1/2) are considered distinct receptors for Wnt5a and are implicated in noncanonical Wnt signaling in organogenesis and cancer metastasis. We found that Wnt5a enhanced proliferation and migration of chronic lymphocytic leukemia (CLL) cells and that these effects were blocked by the humanized anti-ROR1 mAb cirmtuzumab (UC-961). Treatment of CLL cells with Wnt5a induced ROR1 to oligomerize with ROR2 and recruit guanine exchange factors (GEFs), which activated Rac1 and RhoA; siRNA-mediated silencing of either ROR1 or ROR2 or treatment with UC-961 inhibited these effects. Using the ROR1-deficient CLL cell line MEC1, we demonstrated that ectopic ROR1 expression induced ROR1/ROR2 heterooligomers, which recruited GEFs, and enhanced proliferation, cytokine-directed migration, and engraftment potential of MEC1 cells in immune-deficient mice. Notably, treatment with UC-961 inhibited engraftment of ROR1+ leukemia cells in immune-competent ROR1-transgenic mice. Molecular analysis revealed that the extracellular Kringle domain is required for ROR1/ROR2 heterooligomerization and the cysteine-rich domain or intracellular proline-rich domain is required for Wnt5a-induced recruitment of GEFs to ROR1/ROR2. This study identifies an interaction between ROR1 and ROR2 that is required for Wnt5a signaling that promotes leukemia chemotaxis and proliferation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26690702      PMCID: PMC4731190          DOI: 10.1172/JCI83535

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

Review 2.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  Aplysia ror forms clusters on the surface of identified neuroendocrine cells.

Authors:  S E McKay; J Hislop; D Scott; A G Bulloch; L K Kaczmarek; T J Carew; W S Sossin
Journal:  Mol Cell Neurosci       Date:  2001-05       Impact factor: 4.314

4.  ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

Authors:  H Elizabeth Broome; Laura Z Rassenti; Huan-You Wang; Lilly M Meyer; Thomas J Kipps
Journal:  Leuk Res       Date:  2011-08-02       Impact factor: 3.156

5.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

Authors:  Tomoya Yamaguchi; Kiyoshi Yanagisawa; Ryoji Sugiyama; Yasuyuki Hosono; Yukako Shimada; Chinatsu Arima; Seiichi Kato; Shuta Tomida; Motoshi Suzuki; Hirotaka Osada; Takashi Takahashi
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis.

Authors:  Hsin-Yi Henry Ho; Michael W Susman; Jay B Bikoff; Yun Kyoung Ryu; Andrea M Jonas; Linda Hu; Rejji Kuruvilla; Michael Eldon Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-17       Impact factor: 11.205

7.  Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system.

Authors:  I Oishi; S Takeuchi; R Hashimoto; A Nagabukuro; T Ueda; Z J Liu; T Hatta; S Akira; Y Matsuda; H Yamamura; H Otani; Y Minami
Journal:  Genes Cells       Date:  1999-01       Impact factor: 1.891

8.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

9.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

Review 10.  Ror2 as a therapeutic target in cancer.

Authors:  Zufan Debebe; W Kimryn Rathmell
Journal:  Pharmacol Ther       Date:  2015-01-19       Impact factor: 13.400

View more
  80 in total

1.  APC-activated long noncoding RNA inhibits colorectal carcinoma pathogenesis through reduction of exosome production.

Authors:  Feng-Wei Wang; Chen-Hui Cao; Kai Han; Yong-Xiang Zhao; Mu-Yan Cai; Zhi-Cheng Xiang; Jia-Xing Zhang; Jie-Wei Chen; Li-Ping Zhong; Yong Huang; Su-Fang Zhou; Xiao-Han Jin; Xin-Yuan Guan; Rui-Hua Xu; Dan Xie
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 2.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

3.  HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Authors:  Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

4.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

5.  Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells.

Authors:  Falk Heidenreich; Elke Rücker-Braun; Juliane S Walz; Anne Eugster; Denise Kühn; Sevina Dietz; Annika Nelde; Antje Tunger; Rebekka Wehner; Cornelia S Link; Jan M Middeke; Friedrich Stölzel; Torsten Tonn; Stefan Stevanovic; Hans-Georg Rammensee; Ezio Bonifacio; Michael Bachmann; Matthias Zeis; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Marc Schmitz
Journal:  Haematologica       Date:  2017-08-24       Impact factor: 9.941

6.  Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Authors:  Hanna Karvonen; David Chiron; Wilhelmiina Niininen; Sara Ek; Mats Jerkeman; Elaheh Moradi; Matti Nykter; Caroline A Heckman; Olli Kallioniemi; Astrid Murumägi; Daniela Ungureanu
Journal:  Blood Adv       Date:  2017-11-09

7.  STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Orit Uziel; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

8.  The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

Authors:  M Frenquelli; N Caridi; E Antonini; F Storti; V Viganò; M Gaviraghi; M Occhionorelli; S Bianchessi; L Bongiovanni; A Spinelli; M Marcatti; D Belloni; E Ferrero; S Karki; P Brambilla; F Martinelli-Boneschi; S Colla; M Ponzoni; R A DePinho; G Tonon
Journal:  Leukemia       Date:  2019-05-31       Impact factor: 11.528

9.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

Review 10.  Wnt signaling in cardiovascular disease: opportunities and challenges.

Authors:  Austin Gay; Dwight A Towler
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.